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I. INTRODUCTION
Every person's body contains an array of complex and unique informa-
tion, known as DNA.' These segments of proteins and molecules instruct the
body how to develop and function, and are the most basic ingredients of
every person's individuality and distinct life experience.2 Genetic discove-
ries and identification of specific mutations have even contributed to the aca-
demic, corporate, and health communities in uncovering secrets and insight
into the human body, health, and disease.3 An example of a recent genetic
breakthrough was the identification of the human genes associated with he-
reditary breast and ovarian cancer, known as BRCA1 and BRCA2, which
can help patients gain insight as to whether they are at risk of developing
these diseases. 4 In maximizing the benefits and possibilities of genetic dis-
coveries for public health, ease of access "is crucial if basic research is to be
expeditiously translated into clinical laboratory tests that benefit patients in
the emerging era of personalized and predictive medicine." 5
In an effort to reward and protect this new wealth of information and
scientific advancements, the U.S. Patent and Trademark Office (USPTO) has
granted thousands of patents on human genes, including BRCA1 and
BRCA2, 6 which give patent holders "the right to prevent anyone from study-
ing, testing or even examining a gene."7 While the public can in fact benefit
1. See AMERICAN CIVIL LIBERTIES UNION, LEGAL CHALLENGE TO HUMAN GENE PATENTS
2 (May 27, 2009), available at http://aclu.org/pdfs/freespeechl/brca-qanda.pdf [hereinafter
LEGAL CHALLENGE TO HUMAN GENE PATENTS].
2. Complaint at 1, Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office,
669 F. Supp. 2d 365 (S.D.N.Y. 2009) (No. 09 Civ. 4515).
3. See Laurie L. Hill, The Race to Patent the Genome: Free Riders, Hold Ups, and the
Future of Medical Breakthroughs, II TEX. INTELL. PROP. L.J. 221, 222 (2003) ("In order to
understand health and battle disease, scientists seek an understanding of [human] genes, hop-
ing to improve our lives and cure the diseases that plague us. The complete sequencing of the
human [genes] offers unprecedented opportunities for scientific advancement and medical
breakthroughs.").
4. News Release, Pub. Patent Found., ACLU and PUBPAT Challenge Patents on Breast
Cancer Genes: Gene Patents Stifle Patient Access to Medical Care and Critical Research
(May 12, 2009), http://www.pubpat.org/brcafiled.htm.
5. Complaint, supra note 2, at 2; see also Hill, supra note 3, at 228 (Proliferation of
diagnostic genetic testing "will undoubtedly aid physicians in diagnosing patients and in prac-
ticing more effective preventative medicine.").
6. See, e.g., U.S. Patent No. 5,753,441 (filed Jan. 5, 1996) (issued May 19, 1998).
7. LEGAL CHALLENGE TO HUMAN GENE PATENTS, supra note i, at I. Because patent
holders have exclusive rights over the genes themselves, they essentially have "a monopoly
over the patented genes and all of the information contained within them." Id.
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from an efficient patent system, unsound patents or "government sanctioned
restraints on freedom and competition" can also "harm the public by making
products and services more expensive, if not completely unavailable, by pre-
venting scientists from advancing technology, by unfairly prejudicing small
businesses, and by restraining civil liberties and individual freedoms." 8
Association for Molecular Pathology v. United States Patent & Trade-
mark Office9 was originally filed on May 12, 2009 by the American Civil
Liberties Union (ACLU) and the Public Patent Foundation, on behalf of nu-
merous patients and researchers; and it is a new demonstration of concern for
the non-patent holding public, whose interests and voices have been absent
in the decision-making about the current patent system.' ° One of the plain-
tiffs, Genae Girard, was diagnosed with breast cancer at the age of thirty-
six," and in an effort to gain information about treatments and medical deci-
sions, she stated:
I... decided to be diligent about getting second opinions along the
treatment path ... [but] one company has a monopoly on genetic
testing of the BRCA genes. After I was diagnosed with cancer, I
was tested for hereditary risk for breast and ovarian cancers. Mu-
tations on [those] genes can show if you are at higher risk for these
cancers. I tested positive .... [O1nly one company . . . has the
ability to sequence them. I can't get a second sequencing done at a
different company to validate my results. I am thinking about hav-
ing my ovaries removed .... It is uncomfortable making such an
important decision based on only one test .... Having . . . your
ovaries removed [is a] serious procedure[] that cannot be undone.
Patents on human genes should not block patients' ability to get
second opinions. 12
8. American Innovation at Risk: The Case for Patent Reform: Hearing Before the Sub-
comm. on Courts, the Internet, and Intellectual Property of the H. Comm. on the Judiciary,
I 10th Cong. 1 (2007) [hereinafter American Innovation at Risk] (statement of Daniel B. Ra-
vicher, Executive Director, Public Patent Foundation).
9. 669 F. Supp. 2d 365 (S.D.N.Y. 2009).
10. Id. at 369-72; see American Innovation at Risk, supra note 8, at 2 ("[T]he patent
community culture tends to dismiss and exclude the opinions of those it sees as unsophisti-
cated outsiders, but it is mostly because the general public does not yet realize how much the
patent system actually affects them.").
11. American Civil Liberties Union: BRCA-Plaintiff Statements (May 12, 2009),
http://www.aclu.org/print/free-speech womens-rights/brca-plaintiff-statements [hereinafter
Plaintiff Statements].
12. Id. (statement of Genae Girard). Genetic studies "will likely continue to identify
many ... genetic risk factors for common diseases. To continue translating these genetic
discoveries into improved health and quality of life, it is critical to ensure that affordable,
2010]
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The federal case of Association for Molecular Pathology, filed in the
Southern District of New York, attempts to attack genetic patenting through
theories and policies behind patent law, medicine, science, breast cancer ac-
tivism, and "unusual civil liberties argument[s] in ways that could make it a
landmark case."'
' 3
With the advent of technology, patent law addresses many things which
the Framers of the Constitution surely did not anticipate. Nevertheless,
"[p]atent law should not trump [c]onstitutional rights nor be used to impede
its own goal of advancing technology."'' 4 This article will analyze the validi-
ty of DNA patents, specifically the patent on the genes associated with breast
cancer, by applying the novel legal arguments raised in the pending case of
Association for Molecular Pathology, as well as suggest the need for an ex-
emption from infringement liability for exercising constitutional rights such
as freedom of speech, expression, privacy, and bodily integrity. Section I of
this article will begin with background information and history behind patent
law, its constitutional purpose, and how it has been applied to DNA. It will
also discuss the formation and opposition to the BRCA gene patents by ex-
plaining the causes of action in the Association for Molecular Pathology
complaint. Furthermore, Section I will address the need for a new interpre-
tation of gene patents by addressing the problems with the current laws and
precedents, as well as the controversy and debate of patenting something
which is naturally part of the human body. Section I will look to theories
and interpretations of the First and Fourteenth Amendments as new grounds
for attacking patents on human genes. Finally, Section IV will conclude by
discussing the recent cases and how they have changed the analysis of patent
claims in the Federal Circuit courts. It will also anticipate the defenses the
patent holder of the BRCA may raise, as well as the implications of the As-
sociation for Molecular Pathology lawsuit and how patent law might be af-
fected in the future.
interpretable clinical genetic tests will be available to all Americans." Stifling or Stimulat-
ing-The Role of Gene Patents in Research and Genetic Testing: Hearing Before the Sub-
comm. on Courts, the Internet, and Intellectual Property of the H. Comm. on the Judiciary,
110th Cong. 2 (2007) [hereinafter Hearing: Stifling or Stimulating] (statement of Wendy
Chung) (submitted in connection with statement of Marc Grodman, CEO, Bio-Reference
Labs, Inc.).
13. John Schwartz, A Cancer Patient Near Austin, in a Landmark Lawsuit, Challenges a
Company's Monopoly on Two Genes Associated with the Disease: Should a Gene be Pa-
tented? HOUSTON CHRON., May 17, 2009, at 8.
14. American Innovation at Risk, supra note 8, at 16.
[Vol. 34
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II. HISTORY AND CONSTITUTIONAL PRINCIPLES OF PATENT LAW, DNA,
AND THE BRCA GENES
A. Defining and Interpreting Genes and Patentable Subject Matter
Under section 101 of the Patent Act, there is no specific subject matter
proscription on what is patentable. 5 "[L]aws of nature, physical phenomena,
and abstract ideas" are not patentable subject matter.' 6 While a mathematical
formula is not a patentable invention, a patent may exist where there is a new
function produced with the aid of knowledge of such a mathematical formu-
la. 7 Consequently, patents may be obtained for any new or useful process,
machine, manufacture, or composition of matter.'8 However, it is not always
clear how to distinguish an unpatentable principle from a patentable
process. 19 Because of the lack of legislative guidance, courts have extreme
difficulty in determining "what a patent does and does not cover," and the
discretionary "'broadest reasonable construction' standard" is often used to
evaluate the validity of a patent claim. 20 As a result, quality of patent law has
suffered, and private patent holders have the potential ability to deny the
American people of significant advances that may benefit and address the
needs of the public.
2
'
Underlying the constitutional tests and congressional conditions
for patentability is the balancing of two interests-the interest of
the public in being protected against monopolies and in having
ready access to and use of new items versus the interest of the
country, as a whole, in encouraging invention by rewarding crea-
tive persons for their innovations. By declaring a constitutional
15. See 35 U.S.C. § 101 (2006).
16. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). "A principle, in the abstract, is a
fundamental truth." Parker v. Flook, 437 U.S. 584, 589 (1978) (quoting Gottschalk v. Ben-
son, 409 U.S. 63, 67 (1972)) (internal quotations marks omitted); accord Funk Bros. Seed Co.
v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948). Such discoveries "are manifestations of...
nature, free to all men and reserved exclusively to none." Id.
17. Diamond v. Diehr, 450 U.S. 175, 192 (1981).
18. See Flook, 437 U.S. at 588-89.
19. Id. at 589; see also Lab Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S.
124, 134 (2006) (per curiam) (Breyer, J., dissenting) ("[M]any a patentable invention rests
upon its inventor's knowledge of natural phenomena; many 'process' patents seek to make
abstract intellectual concepts workably concrete; and all conscious human action involves a
mental process.").
20. American Innovation at Risk, supra note 8, at 6, 14.
21. Id. at 15. "That fundamental limitation on the scope of what can be patented is
needed to protect the public domain of science and nature from being appropriated through
private property rights." Id. at 17.
2010]
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standard of patentability, however, the Court, rather than Con-
gress, will be doing the ultimate weighing.
22
Currently, the USPTO awards patents on human genes, 23 usually mean-
ing that the patent holder prevents laboratories from analyzing "the gene for
mutations in order to diagnose the presence of a disease or condition, such as
breast cancer," without permission and a high priced licensing fee.24 Ap-
proximately twenty percent of all human genes are patented, including those
associated with Alzheimer's disease, asthma, and some forms of colon can-
cer.25 Ever since the Supreme Court held that a genetically altered bacterium
could be patented in the case of Diamond v. Chakrabarty,26 courts have in-
terpreted patent law to "'include anything under the sun that is made by
m a n .
,27
The Supreme Court has recognized the danger of granting patents that
cover broad subject matter through application-especially in areas that are
vast and unknown.28 Defining the term "gene patent" and what it encom-
passes is not an easy task, and is open to interpretation. 9 With the increase
in knowledge regarding genes, the term "gene" does not only cover the ge-
netic material that encodes a protein in the human body, but also would in-
clude that broad sense of genetic sequencing of the entire segment of the
relevant DNA.3 ° Some argue that gene patents cover molecular constructions
that do not exist in nature and are corresponding structures that are derived
from naturally occurring genes. 3' The debate over patenting genes derives
from the fact that "naturally occurring genes as they exist in their native
state-as they exist in the human body-are unpatentable . . . raw genetic
sequence information;" but the irony of precedent is that the isolation and
"purification of a natural product from its native environment can confer
patentability on the purified [gene]. 32
22. S. Doc. No. 108-17, at 315 (2004).
23. LEGAL CHALLENGE TO HUMAN GENE PATENTS, supra note 1, at 3.
24. Hearing: Stifling or Stimulating, supra note 12, at 3 (statement of Marc Grodman).
"[E]xcept when blocked by exclusive licenses, clinical laboratories compete. We compete on
service.... We compete on quality.... We compete on price .. " Id.
25. LEGAL CHALLENGE TO HUMAN GENE PATENTS, supra note 1, at 3.
26. 447 U.S. 303 (1980).
27. Id. at 309 (quoting S. Rep. No. 1979, at 5 (1952); H.R. Rep. No. 1923, at 6 (1952)).
28. See Brenner v. Manson, 383 U.S. 519, 534-35 (1966).
29. See Christopher M. Holman, The Impact of Human Gene Patents on Innovation and
Access: A Survey of Human Gene Patent Litigation, 76 UMKC L. REV. 295, 307 (2007).
30. Id.
31. See id. at 313 (emphasis added).
32. Id. at 311. Compare Prometheus Labs., Inc. v. Mayo Collaborative Servs., No.
04cvl200 JAH (RBB), 2008 WL 878910, at *9 (S.D. Cal. Mar. 28, 2008), rev'd, 581 F.3d
[Vol. 34
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When patent claims are drafted so that they cover any "recombinant or
isolated form of naturally occurring gene sequence.... they would appear to
cover any biotechnological product or process making or using the claimed
sequence," thereby having a patent over the gene per se.33 In this way, courts
are treating genes "as products in and of themselves, instead of guides to
future product discovery." 34 Accordingly, many argue that granting private
property rights over "such a fundamental aspect of our common human her-
itage strikes some as an affront to human dignity.
35
B. Myriad Problems
[A] "useful" invention is one "which may be applied to a benefi-
cial use in society, in contradistinction to an invention injurious to
the morals, health, or good order of society, or frivolous and insig-
nificant"-and upon the assertion that to do so would encourage
inventors .. .to publicize the event for the benefit of the entire
scientific community, thus widening the search for uses and in-
creasing the fund of scientific knowledge.
36
The patent over the BRCA genes held by Myriad Genetics, a private
biotechnology company in Utah, is an example of a detrimental broad patent
claim. 37 As researchers around the world were getting closer to isolating the
first gene to be associated with hereditary breast cancer, researchers from
Myriad applied for the patent, claiming they were the first to discover the
genetic sequencing.38 The patent relates "generally to the field of human
genetics," covers "methods and materials used to isolate and detect a human
breast and ovarian cancer predisposing gene," and "also relates to the therapy
of human cancers which have a mutation in the [patented] gene, including
1336 (Fed. Cit. 2009) (recently noting that "claims do not gain patentability simply by includ-
ing man-made compositions"-such as gene isolation or purification), and Funk Bros. Seed
Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948) (if there is to be a patent for an invention
from a discovery of unknown natural phenomenon, "it must come from the application of the
law of nature to a new and useful end"), with Holman, supra note 29, at 311.
33. Holman, supra note 29, at 313.
34. Melissa E. Horn, DNA Patenting and Access to Healthcare: Achieving the Balance
Among Competing Interests, 50 CLEV. ST. L. REV. 253, 264 (2003); see also News Release,
Pub. Patent Found., supra note 4 ("'Genes isolated from the human body are no more patenta-
ble than gold extracted from a mountain."').
35. Holman, supra note 29, at 297.
36. Brenner v. Manson, 383 U.S. 519, 533 (1966) (citing Justice Story's decisions on
circuit in Lowell v. Lewis, 15 Fed. Cas. 1018, 1019 (C.C.D. Mass. 1817) (No. 8568)).
37. See Horn, supra note 34, at 269.
38. Id. at 269 & n.162.
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gene therapy [and] protein replacement therapy. 39 Unfortunately, Myriad's
broad patent claim also covers the ownership over the rights to screening for
drugs relating to cancer therapy, as well as screening for gene mutations,
which are essential to understand a person's predisposition to breast and ova-
rian cancer.' °
The suit filed against the USPTO and Myriad asserts that the patent
over the naturally occurring genes should not be patented simply because
they are "'isolated from their natural state and purified."' 41 A gene that is
isolated and removed from a human body functions the same exact way as
does a non-isolated gene inside the body.42 Therefore, removing the gene-a
product of nature--does not change the fact that it still remains and functions
as a product or law of nature.43 Furthermore, by patenting a correlation of
certain mutations with a high risk of breast or ovarian cancer, Myriad has an
unlawful patent over an abstract idea or principle, which allows them to gain
a monopoly over a scientific fact.44
Because the patent is over the actual genes, rather than a genetic test,
scientists and laboratories are prevented from performing alternative testing
on the genes. 45 Breast cancer is not a rare disease, but instead is one of the
leading causes of death among women.46 Right now, there are about two
thousand different mutations along the BRCA genes, 47 but because of My-
riad's broad patent claim and its incomplete genetic testing, little is known
39. U.S. Patent No. 5,753,441 (filed Jan. 5, 1996) (issued May 19, 1998).
40. See id.
41. Complaint, supra note 2, at 19.
42. Id.
43. Id.
44. See LEGAL CHALLENGE TO HUMAN GENE PATENTS, supra note 1, at 4. Laboratory
Corp. of America Holdings involved the natural relationship between elevated hormone defi-
ciencies in B vitamins in human blood, but Justice Breyer and the dissent would have held that
such a correlation is merely an observable aspect of biology and the human body. See Lab.
Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 135 (2006) (per curiam)
(Breyer, J., dissenting). The patent merely covered instructions for reading and understanding
the significance of numbers in light of already acquired medical knowledge. Id. at 137.
45. LEGAL CHALLENGE TO HUMAN GENE PATENTS, supra note I, at 3.
46. See National Cancer Institute, BRCAI AND BRCA2: Cancer Risk and Genetic Test-
ing 2 (2009), available at http://www.cancer.gov/images/documents/abcb7812-al32-4e78-
a532- f002c92fa9b9/fs3_62.pdf.
47. National Cancer Institute, Genetics of Breast and Ovarian Cancer (PDQ): Major
Genes, http://www.cancer.gov/cancertopics/pdq/geneticsbreast-and-ovarian/HealthProfessin
al/page3#Section_ I10 (last visited Apr. 17, 2010).
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about this vast array of information which may be vital to a woman deciding
to undergo preventative surgery4 8
Researchers and clinicians cannot develop or implement new tests
for breast/ovarian cancer linked to BRCA1 or BRCA2 if develop-
ment or implementation involves looking at [the genes]. Women
cannot give their blood or DNA to a researcher or clinician and ob-
tain a second opinion. The effect is to infringe on quality medical
practice and to compromise quality assurance and improvement of
testing.49
C. Impeding the Progress of Science and the Useful Arts
Article I, Section 8 of the Constitution gives Congress the broad power
"[t]o promote the progress of science and useful arts, by securing for limited
times to authors and inventors the exclusive right to their respective writings
and discoveries." 50  Patent law, therefore, is aimed at fostering productive
efforts by providing inventors exclusive rights as an incentive for their re-
search and intellect.5' The rationale behind the purpose and efficiency of
patents is that competitors will be encouraged "to 'invent around' the pa-
tented invention, avoiding wasteful duplication of efforts, and insuring the
eventual dedication of invention to the public with the expiration of the pa-
tent. '52 Particularly in the field of diagnostic testing, competition is "critical
to protection of the public health. ' 3 The Framers of the Constitution, there-
fore, were concerned with "promoting certainty" in addition to the federal
policy objectives.54
48. See Timothy J. Ohara, Note, Patenting the Diagnosis of a Disease: The Scope of
Patentable Subject Matter Based on Labcorp v. Metabolite Labs, 38 GOLDEN GATE U. L. REV.
139, 169-73 (2007); Horn, supra note 34, at 269.
With the breast cancer test,.., more reliable laboratory tests will enable better treatments or at
least enable more rational decisions about electing experimental treatments .... There is a
large number of diseases that could be potentially diagnosed and treated more effectively
through improved diagnostic testing .... However, researchers [cannot improve a genetic test]
if broad diagnostic claims are allowed to remain valid, even when there is a[n] . . . unmet need
for such an improvement.
Id. at 172-73.
49. Complaint, supra note 2, at 18-19.
50. U.S. CONST. art. 1, § 8, cl. 8.
51. See Diamond v. Chakrabarty, 447 U.S. 303, 307 (1980).
52. Hill, supra note 3, at 236.
53. Hearing: Stifling or Stimulating, supra note 12, at 3 (statement of Marc Grodman).
54. Chris J. Katopis, Patients v. Patents?: Policy Implications of Recent Patent Legisla-
tion, 71 ST. JOHN'S L. REV. 329, 346 (1997).
20101
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The underlying policy behind patent law is that discoveries and inven-
tions should be used fully and freely. 55 Genes are at the forefront of public
interest, considering that many of them may hold the keys to life-saving
medical and scientific discovery and innovation.56 Unlike other patents on
more tangible and concrete inventions, genetic discoveries have been public-
ly funded through initial research, but private biotechnology companies, such
as Myriad, and the pharmaceutical industry are those that perform private
research under a patent in order to strive towards a commercially viable
use.57 However, some argue-such as those parties opposed to Myriad's
exclusive rights-that these privately funded patent holders are usually not
interested in making any further end product, or do not have the capability of
doing so.58 When this happens, further development is prevented because
intellectual property rights in genes and diagnostic testing are being pro-
tected too early in the research process.59
In a survey of clinical laboratory directors that perform DNA-based ge-
netic tests-including members of the Association for Molecular Patholo-
gy-a study analyzing the effects of patents on genetic testing revealed that
laboratories were being prevented from continuing already developed genetic
tests because of gene patents. 6° Because genetic laboratories have the ability
and knowledge to perform and translate clinical tests without the publication
of data supplied by gene patents, there is the argument that these gene pa-
tents are not necessary to provide the incentive for others to develop new
innovations in genetic discoveries. 1 On the contrary, when a genetic variant
is discovered and sequenced, such as the BRCA genes, patents are not cru-
cial for the development of the initial invention.62
The patent held by Myriad makes ease of access to genomic discoveries
restricted, and the BRCA genes have been underused in medical and scientif-
ic breakthrough as a result of the over-exclusive use of the patent holder.63 If
the potential uses and benefits of these genetic discoveries are not made
available to the public, access to personalized and predictive medicine is
55. See id. at 338.
56. Horn, supra note 34, at 262.
57. See id. at 263.
58. See id. at 265.
59. See id.
60. See generally Mildred K. Cho et al., Effects of Patents and Licenses on the Provision
of Clinical Genetic Testing Services, 5 J. MOLECULAR DIAGNOSTICs 3,3 (2003).
61. See id. at 8.
62. See id.
63. See Complaint, supra note 2, at 2; see also American Innovation at Risk, supra note
8, at 14 ("[T]here does come a point at which over rewarding patent holders can in fact retard
technological development.").
[Vol. 34
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restricted.' Because the BRCA genes are not the only genes or factors asso-
ciated with breast cancer, there is still a lot to be uncovered about the disease
in order to maximize the benefits of genetic testing and technology. 65 How-
ever, because Myriad can decide how many tests will be done, and who is
entitled to receive and perform the tests, only a limited number of individuals
are using and testing the new information.66 In a statement regarding the
danger of patents on patients' rights by prohibiting medical innovation, the
American Society for Clinical Pathology reported:
[Myriad's] [g]ene patents limit the broad availability of diagnostic
tests due to the simple fact that laboratory scientists are prohibited
from performing genetic tests because of patent enforcement and
the threat of litigation. As a result, the market is dominated by a
single provider, eliminating competition and scientific diversity,
which ultimately drives up costs .... Such patents stifle the inno-
vative process, negating further refinement in test methodology,
improvements in quality, and access to testing .... 67
Perhaps the most disturbing effect of the Myriad patent over the BRCA
genes is that because there is little incentive for competition due to fear of
litigation, there is little incentive to improve the quality of testing performed
by Myriad.68 As a consequence, the company continues to deliver confusing
and ambiguous results.69 Because of the limited avenues of testing provided
by Myriad, women and their families are left without knowing whether they
should make a life-altering decision affecting their bodies, health, and value
of life.
70
64. Complaint, supra note 2, at 2.
65. See Horn, supra note 34, at 272-73 ("Science has moved away from thinking that
one gene is responsible for each disease .... [M]ultiple genes work in coordination; therefore,
in order to treat or cure a disease, research and experimentation upon many genes and their
functions is necessary.").
66. Id. at 269,275.
67. Plaintiff Statements, supra note 11. "In breast cancer genetic testing . .. we have
seen no innovation in the past five years-since Myriad Genetics introduced its most recent
test." Id. (statement of Dr. Harry Ostrer).
68. Hearing: Stifling or Stimulating, supra note 12, at 4 (statement of Dr. Wendy
Chung).
69. See id.
70. See id.
2010]
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I. The Need for Dynamic Constitutional Interpretation
As those in the medical profession continue to be cooperative and open
about their intellect and ideas within their studies, the case against Myriad
demonstrates the need to interpret gene patent claims through a new alterna-
tive means of constitutional purpose.71 When the Framers of the Constitution
drafted the provision regarding congressional authority over patents, the
science of genetic sequencing was surely not in their field of thought or im-
agination.72 Therefore, like the Constitution itself, patent claims are drafted
broadly to adapt to current social and legal issues in light of precedents that
are already understood and well known.73 Patent holders should not be able
to construct their own claims and laws in order to fulfill their own private
interests; rather, only Congress holds the broad power to grant patents to
fulfill the constitutional intent of "promoting the sciences and useful arts.
74
When patents no longer function as the Framers intended, patents are
unconstitutional. As the plaintiffs in Association for Molecular Pathology
contend, patent law affects many fundamental rights.75 Awarding a patent
for a human gene, such as those associated with breast cancer, prevents
scientific advancement and intellectual freedom by obstructing the free ex-
change of information that is vital to the workings of democracy.
III. NOVEL LEGAL CHALLENGES:
GENE PATENTS AS A CIVIL LIBERTIES ISSUE
In order to uphold the validity of the plaintiffs' unprecedented constitu-
tional challenges against patenting genes in Association for Molecular Pa-
thology, one must understand the inner workings of the relationship between
patent law and constitutional fights in order to appreciate these novel argu-
ments, keeping in mind that the Constitution, as a political invention, and
patents, as a physical invention, are both, in some sense, a source of intellec-
tual, social, and human development.76 Because Congress' power over pa-
tents derives from the Constitution itself, "constitutional interpretation must
be freed from the [past] circumstance[s] of the Framers," in order to allow
71. See Katopis, supra note 54, at 387.
72. See Thomas K. Landry, Constitutional Invention: A Patent Perspective, 25 RUTGERS
L.J. 67, 92-94 (1993) ("It has been necessary to adapt the Constitution to our advancing tech-
nologies .... The case for accommodation of progress without originalist objections ... is
supported by the interpretative accommodation of progress in patent law.").
73. See id. at 90-91.
74. U.S. CONST. art. I, § 8.
75. See generally Plaintiff Statements, supra note 11.
76. See Landry, supra note 72, at 97 (emphasis added).
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modem interpreters and judges to accommodate the changes caused by the
new unknown realm of intellectual property that is engraved in genetic
sciences."' The power granted to a patent holder is created by constitutional
power.78 Thus, constitutional law demands the flexibility and endurance of
protections of fundamental liberties and core principles of a democratic so-
ciety. To achieve the constitutional requisites of patent law, one must devel-
op new conceptions of constitutional rights as exemptions from governmen-
tal power.79 Patents exist only for a limited lifetime.80 The Constitution lives
forever. The enumerated power granted to Congress in Article I "is not an
end in itself for the typical citizen in whose name the Constitution was rati-
fied as supreme law."
81
A. Granting Exclusive Licenses Infringe on First Amendment Rights
Although the First Amendment states, "Congress shall make no law...
abridging the freedom of speech, or of the press, 82 the text also applies to
other forms of conduct and communication, such as expression of ideas and
knowledge, self-expression, and the dissemination of information. 83 Patent
law serves the same purpose as does the First Amendment-to place know-
ledge and innovation on an equal playing field in order to develop new ideas
based on actual merit and effort, and not based on what is dictated by more
powerful organizations and the government. 84 Therefore, if a gene patent
prevents the progress of scientific and medical breakthroughs and innova-
tions, the First Amendment is inevitably implicated because the federal gov-
ernment has awarded the patent holder with the exclusive rights to deny oth-
ers from researching the genetic sequences, which results in the silencing of
future knowledge, ideas, and expression. 85 After all, "[tihe first amendment
is there so as to enrich the gene pool of ideas. 86
77. Id.
78. See U.S. CONST. art. 1, § 8.
79. See SOTIRIOS A. BARBER, ON WHAT THE CONSTITUTION MEANS 146-47 (1984).
80. See Hill, supra note 3, at 233.
81. BARBER, supra note 79, at 106.
82. U.S. CONST. amend. 1.
83. See DANIEL A. FARBER, THE FIRST AMENDMENT 1 (1998) ("[Tlhe bare text of the First
Amendment provides only a hint of the ultimate contours of legal protection.").
84. Paul Heckel, Patents, Ecology and the First Amendment, PANDAB, July 6, 1998,
http://www.pandab.org/patents-ecology-first-amendment.html. ("The role of patent laws
plays in encouraging innovation is the same role as the first amendment plays in encouraging
open political discussion and thus change: they make it possible to challenge entrenched and
powerful established interests.").
85. See generally FARBER, supra note 83. It is important to "preserve a predominantly
free enterprise economy, [and] the allocation of our resources ... will be made through nu-
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In the case of Association of Molecular Pathology, the patent for the
BRCA genes is drafted in such a way that it gives Myriad not only exclusive
rights but also exclusive license, which makes it more difficult for others to
express opinions and share ideas regarding the breast cancer enigma.87 If
patents such as the one held by Myriad are an unconstitutional private own-
ership of a basic idea or human knowledge, then the gene patent therefore
infringes on the First Amendment rights of researchers, doctors, patients, and
the American public, who have a fundamental right to access known, benefi-
cial public information.88 There are thousands of physicians, researchers,
pathologists and scientists who are able and willing to look at and sequence a
person's BRCA genes and determine whether a mutation exists that would
increase that person's risk of breast or ovarian cancer.8 9 Genes contain the
necessary information towards developing cures and therapies for diseases;
however, "[t]he only thing that prevents those doctors and scientists from
looking at the human BRCA1 and BRCA2 genes is Myriad's patents. 90
1. Self-Realization Values and the Attainment of Truth in the Marketplace
of Ideas
Intrinsic in the First Amendment is the importance of attaining truth
through the exchange of facts and personal fulfillment. 9' "If people lack
merous private economic decisions. It is a matter of public interest that those decisions, in the
aggregate, be intelligent and well informed. To this end, the free flow of commercial informa-
tion is indispensable." Id. at 152 (quoting Va. State Bd. of Pharmacy v. Va. Citizens Con-
sumer Council, Inc., 425 U.S. 748, 765 (1976)) (emphasis added).
86. Heckel, supra note 84 (emphasis added).
87. See Plaintiff Statements, supra note 11.
When we have only one laboratory that we can use, we have no way of saying to our patients,
"let's do this a different way" or "let's ask someone else." Sometimes our patients say, "Let's
try another laboratory. Maybe this laboratory made a mistake or maybe there is another me-
thod to look at genes." Together we make an effort to exhaust all of the possibilities. Having
only one laboratory to perform a test because the genes are patented restricts our ability to ask
for another opinion. A second opinion is frequently a must in medicine when there are impor-
tant decisions to be made. We should also have the opportunity to have a second or even a
third opinion when it comes to genetic testing.
Id. (statement of Elsa Reich, Dep't of Pediatrics at N.Y. Univ. School of Med.); see also Hill,
supra note 3, at 233. Since Myriad holds a patent on the molecule itself, this "confers the
broadest protection to the patentee because the claimed molecule will fall within the scope of
the patent regardless of what process is used to make the product." Id.
88. See LEGAL CHALLENGE TO HUMAN GENE PATENTS, supra note 1, at 7 (The public has
a "right to benefit from scientific breakthroughs that advance medical research.").
89. Complaint, supra note 2, at 25.
90. Id. The BRCA genes are pure information-not inventions-and in order to invent
around them, the actual sequences must be freely available to utilize. Id. (emphasis added).
91. FARBER, supra note 83, at 4.
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access to a wide range of ideas, they are prevented from imagining the full
range of possibilities in their lives."92 From the viewpoint of those wishing
to study and research BRCA genes, and other genetic disorders and treat-
ments related to them, the repressive nature of the patent system can confine
their ability to express their perspectives, thereby taking a sense of self-
ownership away from them.93
The Supreme Court once said that "[o]ur [n]ation is deeply committed
to safeguarding academic freedom, which is of transcendent value to all of us
and not merely to the teachers concerned. That freedom is therefore a spe-
cial concern of the First Amendment . . . 94 For those who have devoted
their lives and studies to uncovering the endless possibilities in the field of
genetic science, the patent law system seems to work against their devotion
for their work and desire to acquire knowledge.95 Patents are economically
driven, but in the world of science and research, personal wealth often takes
a back seat to recognition among peers and self-gratification. 96 Therefore, in
the case of the plaintiffs opposing the BRCA gene patent, the patents are
unnecessarily restrictive in that they deny the personal quest for scientific
truth and progress in answering a usually narrow question with a specific
answer.97 By patenting the BRCA genes, the government is sanctioning the
patenting of useful scientific information and the abstract idea that mutations
occur outside of the body.98 In fact, little is known to certainty regarding
92. Id.
93. See id.; see also Brian C. Murchison, Speech and the Self-Realization Value, 33
HARV. C.R.-C.L. L. REV. 443, 446 (1998) (explaining that the freedom to participate in deci-
sions is a necessary ingredient to a democratically-governed society).
94. Keyishian v. Bd. of Regents, 385 U.S. 589, 603 (1967).
95. See generally Plaintiff Statements, supra note 11. There is a "strong disincentive to
perform translational research, [which] applies to many other academically based genetics
testing laboratories, thus depriving patient populations from the active research involvement
of some of the best scientists and institutions in the world." Id. (statement of David H. Led-
better, Ph.D.).
96. See Hill, supra note 3, at 243. Although there might be some underlying economic
incentive behind genetic sciences, the foremost goal of scientists is defining individual
achievement. Id. (citing John M. Golden, Biotechnology, Technology Policy, and Patentabili-
ty: Natural Products and Invention in the American System, 50 EMORY L.J. 101, 147-49
(2001)).
97. See id. at 244. The validation of scientific findings, which are confirmed by others in
the field, are vital in searching for scientific truth among different techniques and ways of
approaching the scientific enigma in question. Id. (citing Rebecca S. Eisenberg, Patents and
the Progress of Science: Exclusive Rights and Experimental Use, 56 U. CHI. L. REV. 1017,
1048-53 (1989)).
98. See Complaint, supra note 2, at 23 (What is patented is that the two forms of the
BRCAI and BRCA2 genes have been made different because of nature-an abstract idea not
known to be true.).
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breast cancer genetics, and if these ideas are treated as any other traditionally
patented products, the public "marketplace of ideas" will be burdened by
patent regulations.99
Because the significance of the test results of BRCA genetic tests are
often unclear and meaningless, the results lack an objective quality-even
though other physicians who actually interpret these results have the ability
to perform further testing." When a patient or a physician receives a test
result of "variants of unknown significance," it can be confusing because
there is no way to acquire a definite answer whether the patient can surely be
at a higher risk of developing cancer.' °' Especially in the realm of medicine
and health, the providers of beneficial services should act with the patients'
best interests in mind.
Progress in the natural sciences is not remotely confined to find-
ings made in the laboratory. Insights into the mysteries of nature
are born of hypothesis and speculation. The more so is this true in
the pursuit of understanding in the groping endeavors . . . the con-
cern of which is man and society .... [I]f understanding be an es-
sential need of society-inquiries into these problems [by those in
their respective occupations], speculations about them, stimulation
in others of reflection upon them, must be left as unfettered as
possible. Political power must abstain from intrusion into this ac-
tivity of freedom [that is a special concern of the First Amend-
ment]. 102
By allowing Myriad Genetics to hold the power and wealth of vital in-
formation to sick patients, the quality of health care inevitably suffers. The
complaint of Association for Molecular Pathology points to the fact that
"[f]or at least some portions of the life of the [BRCA genes], Myriad did not
perform certain tests that were known to reveal additional mutations that
99. See FARBER, supra note 83, at 5 (noting that society can benefit from a wide array of
ideas in order to conceptualize and confirm true ideas by disproving false, or bad, ones).
100. See generally Cho et al., supra note 60 (finding that genetic laboratory directors felt
that gene patents delayed or inhibited research, especially regarding genetic testing they had
already been performing before the issuance of a gene patent). While there exists an experi-
mental use exemption for infringement liability, it has been interpreted to have no significant
effect on the patent system and researchers' rights. See American Innovation at Risk, supra
note 8, at 16 (noting that "it seems perverse to subject scientific research to the risk of in-
fringement liability .... [but] legislative action is now [needed] to restore the proper balance
between the private rights of patent holders and the public interest in advancing technology.").
101. Plaintiff Statements, supra note 11 (statement of Harry Ostrer, M.D.).
102. Sweezy v. New Hampshire, 354 U.S. 234, 261-62 (1957) (Frankfurter, J., concur-
ring).
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increased the risk of breast and/or ovarian cancer." 10 3 Myriad's patent over
the BRCA genes, therefore, does not coincide with the constitutional purpos-
es behind the Patent Act and merely has the effect of prohibiting others in the
medical and scientific fields from disseminating useful knowledge and
ideas. °4 Contrary to what proponents of patents on genes may argue about
negative impacts of duplicative research, multiple teams of researchers can
actually scrutinize the same problems in order to efficiently reach and vali-
date a particular result.'05 In fact, it is likely that when multiple individuals
research the same subject matter-BRCA genes and the significance of their
mutations-the "marketplace of ideas" can be filled with new implications
and conclusions arising from the initial discovery.'06
2. Chilling Effects Doctrine and the Public's Right to Know
Today, doctors are viewed as individuals who are part of a prestigious
team and work together by sharing insights and intellectual honesty, in order
to inform each other and their patients. 10 7 However, because Myriad does
not share the information that is personally held in its large database of
BRCA1 and BRCA2 data, researchers are "chilled from engaging in research
on other genes," despite the fact that it is well-known that the BRCA genes
"interact with other genes in ways that are not yet fully understood."'0 8 Up
until this point in time, there have only been two lawsuits involving Myriad
and its BRCA patents, but neither proceeded far enough to reach a substan-
tive ruling.1°9 Consequently, "none of the fears" and potential harm caused
by gene patents have materialized, despite the fact that many would agree
that declaring private ownership of a human gene is morally inappropriate. °"0
One lawsuit for infringement involved the University of Pennsylvania, which
had been providing commercial genetic testing for the BRCA1 gene, but
decided to cease testing in order to avoid litigation."' This demonstrates the
103. Complaint, supra note 2, at 26.
104. See Brenner v. Manson, 383 U.S. 519, 536 (1966) (Congress did not intend for a
patent to be "a hunting license. It is not a reward for the search, but compensation for its
successful conclusion.") (emphasis added).
105. Katopis, supra note 54, at 390.
106. See id. ("'The benefits of the parallel research strategy include, increased returns
corresponding to the number of alternatives; [as well as] a higher rate of 'learning'.
(citing Eisenberg, supra note 97, at 1065).
107. Id. at 388.
108. Complaint, supra note 2, at 28.
109. Holman, supra note 29, at 346-47.
110. Id. at 352.
111. Id. at 347.
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"chilling effect of gene patents" and the negative impact on access to health-
care and genetic testing."
12
The chilling effect doctrine, as a basis for protecting First Amendment
rights, understands that when the expression of viewpoints and freedom to
engage in certain activities is limited because of indirect government regula-
tion, a chilling effect occurs because of the abridgment of First Amendment
freedoms.1 3 Myriad, as the exclusive holder of the rights to the BRCA
genes, charges approximately $3000 for a genetic test, and charges high
amounts for licensing fees." 4 However, even if these licensing practices are
available, the high prices and fees have led researchers to shut down labs and
halt research efforts."5 Lab shut-downs result in the chilling effect of not
being able "to gain access to the latest information [and] can result in a dis-
covery... not being made at all." '1 6 Plaintiff Arupa Ganguly is an Associate
Professor in the Department of Genetics at the Hospital of the University of
Pennsylvania whose field of study involved clinical practice relating to
breast cancer, but she was forced to discontinue her research because of a
cease-and-desist letter from defendant Myriad." 7 "If [Myriad's patents] are
invalidated now, she would seriously consider resuming clinical practice that
is now prohibited.""' 8 First Amendment rights, and the chilling effect doc-
trine, are implicated through the exercise of patent rights held by Myriad
because it affects those who have put time and effort and devoted their lives
to studying breast cancer and related genetic disorders.
When there is a lack of competition in diagnostic testing, such as the
current situation of BRCA genetic testing, different viewpoints and avenues
for testing are chilled, as many providers have been prevented from provid-
ing genetic testing for breast cancer." 9 Because Myriad has the ability to
refuse to offer certain diagnostic testing, there is a reduction in possible ac-
cumulated knowledge. The chilling effects do not only harm certain individ-
uals wishing to assemble together in order to acquire, share, and reap the
benefits of their knowledge and viewpoints, but also harms society and the
general public--especially in the world of health care-because "[t]he great-
112. Id.
113. DANIEL J. SOLOVE, UNDERSTANDING PRIVACY 178 (2008).
114. Complaint, supra note 2, at 27; Horn, supra note 34, at 275.
115. Horn, supra note 34, at 275.
116. Id.
117. Complaint, supra note 2, at 6.
118. Id.
119. See Plaintiff Statements, supra note II (statement of Stephen T. Warren, Ph.D.)
("Even if an improvement in testing methodology is available, another laboratory is prohibited
by the exclusive license from implementing the testing refinement.").
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est benefit DNA patents bring is the promise and potential of curing, treating,
diagnosing, and eliminating medical conditions that afflict all.'
' 20
When patents on DNA have the effect of privatizing biomedical re-
search, they chill upstream and downstream research. 121 Where clinical la-
boratory directors and genetic physicians would otherwise have the right to
freely practice their own trade, patents on DNA force them to deal and li-
cense with the private patent holders. 22  Therefore, the monopoly of the
BRCA genes held by Myriad preempts any alternative avenues for commu-
nicating related expression and viewpoints regarding breast cancer and ge-
netic disorders, effectually chilling, undermining, and blocking the public's
right to benefit from better medical care for hereditary forms of breast can-
cer. 23 "As it currently stands, because of exclusive gene testing patents, no
single laboratory in the United States could offer full genome sequencing for
clinical purposes."' 24 Therefore, by raising First Amendment challenges to
the patents held by Myriad, the plaintiffs in Association for Molecular Pa-
thology have the ability to prove that the BRCA gene patents hamper the
progress of useful arts and sciences on new legal bases that voice concern for
the chilling effects of restricting the bounds of practicing medicine and si-
lencing new research. 121 "'What they have really patented . . . is know-
ledge.""
126
120. Brian Gargano, The Quagmire of DNA Patents: Are DNA Sequences More Than
Chemical Composition of Matter?, 2005 SYRACUSE SCI. & TECH. L. REP. 3, 36 (2005) (empha-
sis added).
121. See Horn, supra note 34, at 264 ("[P]atents limit the availability and raise the cost of
the therapeutic and diagnostic end products because the patents are owned too far upstream in
the research and development process.").
122. See Cho et al., supra note 60, at 3 (finding a significant number of respondents re-
ported that they had decided to stop performing genetic tests for clinical purposes because of
patents or licenses).
123. See Hearing: Stifling or Stimulating, supra note 12, at 6 (statement of Marc Grod-
man) ("[W]hen an exclusive license is granted, research on finding new genes that will en-
hance the clinical significance of the original discovery is brought to a halt.... In the area of
genetic testing, exclusivity is a formula for mediocrity.").
124. Plaintiff Statements, supra note 1 I (statement of Stephen T. Warren) (emphasis omit-
ted). Allowing a broad patent claim "amounts to granting a patent on the practice of medi-
cine." Ohara, supra note 48, at 147.
125. Broad medical diagnostic patents "could have a chilling effect on free speech in terms
of communicating good medical advice or the practice of medicine." Ohara, supra note 48, at
165 & n.248.
126. Schwartz, supra note 13 (quoting statement of Christopher Hansen, Senior National
Staff Counsel, American Civil Liberties Union). "Gene patents implicate the First Amend-
ment because the very thought that there is a relationship between specific genetic mutations
and diseases has been patented and because scientific inquiry is limited." LEGAL CHALLENGE
TO HUMAN GENE PATENTS, supra note 1, at 5. The monopoly that is created by granting ex-
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B. Fourteenth Amendment, Fundamental Rights, Privacy, and
Informed Consent
"'Imagine if one of your family members was making a decision about
surgery to remove her breasts [or ovaries] after a gene test result placed her
at high risk for breast [or ovarian] cancer and there was no place to get an
independent test done to confirm the results .. ,, ."" This is the disturbing
situation of many patients looking for some insight into their own personal
diseases or those of family members. The rapid pace at which scientific and
genetic technology are advancing foreshadows the continuing concerns over
"genetic privacy, informed consent, and the ownership and custodianship of
patient data. ... ,,128 When a person is denied the information that might be
readily available concerning his or her own health, the exclusion has an ef-
fect of taking away a person's constitutional right to control over his or her
own life and liberty.
The Fourteenth Amendment states that a person shall not be deprived of
"life, liberty, or property, without due process of law; nor deny to any person
within its jurisdiction the equal protection of the laws.' 29  The Supreme
Court has recognized that individual rights and liberty interests encompass-
ing individual sovereignty, bodily integrity, and informed consent are vital in
order to protect and guarantee the most important decisions a person will
make in her lifetime.1 30 The freedom over one's own body and health has
been characterized as being pivotal to the liberties encompassed in the Four-
teenth Amendment. 131 Modern constitutional analysis, in addition, encom-
passes certain "zones of privacy, which were evident and sustained under
law since before the nation's founding."'1
32
In the world of therapeutic and non-therapeutic medical experimenta-
tion, a patient has the fundamental right to be informed through disclosure of
the benefits and risks of medical procedures-including complete and accu-
rate information containing a full description of a patient's condition-to
clusive rights over "fundamental pieces of knowledge infringes on First Amendment rights,
which protect the freedom of scientific inquiry and the free exchange of knowledge and
ideas." Id.
127. Press Release, Am. College of Med. Genetics, ACMG Joins Lawsuit Challenging
Patents on Breast Cancer Genes (May 12, 2009) (on file with author) (quoting statement of
Michael S. Watson, Exec. Director of the Am. College of Med. Genetics).
128. David Korn, Privacy and the Research Use of Human Tissue, in GENETIC TESTING
AND THE USE OF INFORMATION 73 (Clarisa Long ed. 1999).
129. U.S. CONST. amend. XIV, § I.
130. See Planned Parenthood of S.E. Pa. v. Casey, 505 U.S. 833, 844-46 (1992).
131. See ROBIN D. BARNES, THE NATURE AND SCOPE OF INDIVIDUAL RIGHTS 43 (2008).
132. Id.
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maintain autonomy over his or her body.1 33 In the case of Myriad Genetics
and its patents to the BRCA genes, breast cancer victims and those whose
family members have succumbed to the disease have been excluded from
information regarding personal information and the use of personal data.
13 4
When people are excluded from participating in how their personal data con-
tained in their genes can be used, there is an effectual feeling of uncertain-
ty.1"5 The lack of ability to maintain knowledge of one's own bodily and
genetic information can make a person powerless. 13 6 In the realm of possibil-
ities genetic information can reveal, the patent on the BRCA genes prevents
the discovery of new personal facts about a person that result from the ag-
gregation of information taken from the original, isolated gene.1 37 Informa-
tion contained in a person's genes is vital to understanding how the body
functions and reacts. 138 Therefore, in order to make intelligent and informed
decisions about one's body, one must have the most accessible and accurate
information. The women who are denied testing because they are unable to
afford Myriad's exorbitant diagnostic fees are therefore denied their funda-
mental rights to make informed decisions regarding choices over their body
and health. 1
39
1. Reproductive Liberty and Gender Discrimination
Reproductive liberty is a certain autonomy encompassed in privacy over
certain intimate decisions. 140 By focusing on the general realm of reproduc-
tive health and freedom, discrimination and subordination of women can be
found because the patents restrict a woman's freedom to choose to reproduce
at her will.14' Because reproductive liberty is a non-express fundamental
constitutional right, some scholars believe it falls under a penumbra of rights
under a right of privacy. 142 However, "even if privacy is taken to mean [re-
productive] autonomy, that kind of freedom of decision making presupposes
that the one exercising it has control over the ... act or its effects."' 143 Breast
cancer and ovarian cancer are diseases that mainly affect women, who as a
133. See GEORGE P. SMITH II, GENETICS, ETHICS AND THE LAW 40-41 (1981).
134. See Complaint, supra note 2, at 2, 18.
135. SOLOVE, supra note 113, at 134-35.
136. Id.
137. See Complaint, supra note 2, at 2, 18.
138. See id. at 2, 16.
139. Id. at 2-3.
140. See Roe v. Wade, 410 U.S. 113, 152-53 (1973).
141. See MARCIA MOBILIA BOUMIL ET AL., LAW AND GENDER BIAS 20 (1994).
142. Id.; see, e.g., Roe, 410 U.S. at 152-53.
143. BOUMIL ET AL., supra note 141, at 19-20.
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class, are unequally burdened by Myriad's patents. 44 "Because of this, re-
productive liberty must be found in the Equal Protection Clause of the Four-
teenth Amendment."'
45
Because of the patent over the BRCA genes, the collaboration of some
of the nation's most experienced people in the world of cancer and genetics
are missing, and these women are suffering as a result. 46 Therefore, a wom-
an who is denied the completely informed decisional authority to remove her
ovaries is inevitably denied her fundamental right to choose freely whether
or not to have a child. 147 One of the plaintiffs in Association for Molecular
Pathology, Lisbeth Ceriani, submitted a blood sample, as recommended by
her oncologist, in order to determine if she should undergo surgery in order
to reduce her risk for ovarian cancer.
48
However, she was notified that Myriad would not process the
sample. Even though her insurance has informed her that it would
cover the BRCA genetic test, Myriad will not accept [her] cover-
age. Ms. Ceriani is unable to pay the full cost out-of-pocket and,
to date, has not been tested. Without the genetic test results, she
cannot determine the best medical course for herself. If the patents
are invalidated, Ceriani is ready, willing, and able to utilize [other]
additional resources for testing and research. 149
For a woman who is deciding to remove her ovaries, it is essentially a
decision to terminate her ability to give birth to a child. Something that the
Supreme Court has also recognized as part of substantive due process is a
fundamental right to be free from governmental interference affecting a per-
son's decision whether or not to terminate-or in this case, prevent-a preg-
nancy.150 The possibility of unnecessarily preventing someone from having
children brings back thoughts of Social Darwinism and the theory of eugen-
ics, which has been held to be morally unacceptable and inhumane.' 5' When
a woman is not informed to a sufficient degree to make a completely volun-
tary decision to make herself infertile, but a more knowledgeable physician
and genetic counselor is able to make such a recommendation for her, the
144. See Complaint, supra note 2, at 26, 29; BOuMIL ET AL., supra note 141, at 20.
145. BOUMILETAL., supra note 141, at 20.
146. Complaint, supra note 2, at 2, 18-19.
147. See id. at 2.
148. Id. at 10.
149. Id.
150. See generally Roe v. Wade, 410 U.S. 113 (1973).
151. See BOuMIL ET AL., supra note 141, at 57.
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right to procreate is no longer a fundamental choice to uphold the existence
and survival of one's familial line.
52
2. Family Rights
In the doctor-patient relationship, there are many issues regarding dis-
closure to family members regarding knowledge of a certain genetic condi-
tion.'53 The genetic information of patients wishing to access BRCA testing
may not only reveal information regarding their own personal risks of devel-
oping cancer, but also may answer questions about relatives who have died
of breast or ovarian cancer.154 Currently, Myriad only offers genetic testing
on blood samples and has not developed any other methods of testing
through human tissue.1 5 If the family members have passed away due to
breast or ovarian cancer, the only available specimen available for testing is
human tissue from a previously removed cancerous tumor because the blood
is no longer available. 156 Therefore, family members wishing to have Myriad
perform genetic testing are denied from doing so, despite the fact that other
laboratories in the country are able to do so. 157 The family, as a collective
unit, has a common public interest and private right to claiming the informa-
tion in question.
158
3. Equal Protection as a Basis for Discriminatory Genetic Testing Quality
In 2005, approximately 1,433 BRCA1/BRCA2 genetic tests resulted in
genetic variations of unknown significance. 159 Unfortunately, the problemat-
ic test results provided by Myriad disproportionately affect African Ameri-
cans, Hispanics, and Asian women, who have been less likely to volunteer in
research studies to add information to genetic databases.1'6 "[T]here are mul-
l 52. See id. at 20.
153. See Dean Bell & Belinda Bennett, Genetic Secrets and the Family, in GENETICS AND
GENE THERAPY 209, 209 (Shiela A.M. McLean ed., 2005).
154. See id. at 210. "[E]ven if family members are not actually tested, in order to verify a
diagnosis clinical practice normally entails obtaining information about family members in
successive generations leading to the creation of a family pedigree." Id.
155. Hearing: Stifling or Stimulating, supra note 12, at 4 (statement of Dr. Wendy
Chung).
156. Id.
157. See id.
158. See Lawrence 0. Gostin, Genetic Privacy, in GENETICS AND GENE THERAPY 241, 304
(Sheila A.M. McLean ed., 2005).
159. Hearing: Stifling or Stimulating, supra note 12, at 3 (statement of Dr. Wendy
Chung).
160. Id.
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tiple links among race, gender, and genetics, . . . [but] [g]enetic differences,
too, are typically regarded as biological and 'real,' justifying differences in
treatment, with too little attention to the social choices involved.' 6' Under
Susan M. Wolf s approach to an antidiscrimination approach, the lack of
knowledge of genetic information of minority populations results because "a
norm exists . . . that all should be treated in conformance.' '162 The Myriad
genetic testing:
counsels that people of color should be treated like whites .... It
bifurcates the world into those who nonproblematically fit the
norm . . . and those who are problematically different .... In ge-
netic terms, this means bifurcating the world into those with non-
problematically "normal" genotypes and those with problematical-
ly "abnormal" ones. 163
Because no person has the same exact genetic makeup, it is important to
have a genetic database containing variants in a wide range of ethnicities, in
order to analyze and conserve the information to compare and correlate these
variants. ' 64 The Myriad gene patents, however, result in disproportionate
medical exclusion of minorities.' 65 Because Myriad faces no competition in
the market, "there is no incentive for them to improve the quality of data
interpretation ... 166
IV. CONCLUSION: CASE IMPLICATIONS AND SUGGESTIONS FOR FUTURE
APPROACHES
The outcome of Association for Molecular Pathology is still indefi-
nite. 167 "The rock was tossed into the biotech pond on March 29, 2010, when
161. Susan M. Wolf, Beyond "Genetic Discrimination": Toward the Broader Harm of
Geneticism, in GENETICS AND GENE THERAPY 159, 159 (Sheila A.M. McLean ed., 2005) (cit-
ing Rochelle Dreyfuss & Dorothy Nelkin, The Jurisprudence of Genetics, VAND. L. REV. 313,
315-17 (1992)).
162. Id. at 161.
163. Id. at 161-62.
164. See Hearing: See Stifling or Stimulating, supra note 12, at 3-4 (statement of Dr.
Wendy Chung).
165. See id. at 3.
166. Id. at4.
167. See Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 669 F. Supp.
2d 365, 369-70 (S.D.N.Y. 2009). Since completion of this paper in the summer of 2009,
Defendants moved to dismiss, and Plaintiffs moved for summary judgment on August 26,
2009. Id. at 370. "Defendants' motion to dismiss, and Plaintiffs' motion for jurisdictional
discovery were heard and marked fully submitted on September 30, 2009, and Plaintiffs'
[Vol. 34
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Judge Robert W. Sweet issued a 156-page opinion holding that the purifica-
tion of a natural product (in this case, human BRCAI and BRCA 2 genes),
without more, could not transform it into patentable subject matter."'68 In
reaching the conclusion, Judge Sweet relied on Supreme Court precedent,
and determined that the proper test to analyze the patents was "whether the
invention had 'markedly different characteristics' from the natural prod-
uct.' ' 16 9 The court ultimately invalidated the human gene claims by looking
"at the isolated DNA for the BRCA1 and BRCA2 genes as claimed in the
patents, and held that it was unpatentable as it was not markedly different
from native DNA as it exists in the human body."'7 ° With regards to My-
riad's method claims, Judge Sweet sided with the plaintiffs and ruled that the
patents were indefinite and "were directed to an unpatentable abstract mental
process.''
The case is surely to have an effect in the world of policy and law as it
relates to the world of intellectual property and medicine. 72 Because of the
future wealth that awaits in the pharmaceutical and health care industries as a
result of genetic discoveries, it is unlikely that a court would completely ban
motion for summary judgment was stayed pending resolution of Defendants' motion to dis-
miss." Id. at 369. In their motions to dismiss, Defendants USPTO and Myriad directors ar-
gued that Plaintiffs lacked standing to sue for constitutional violations and to challenge the
validity of the patents. See generally id. at 383-92 (explaining why Plaintiffs have established
standing); see also Defendant U.S. Patent & Trademark Office's Memorandum of Law in
Support of Motion to Dismiss at 4-9, Ass'n for Molecular Pathology v. U.S. Patent & Trade-
mark Office, 669 F. Supp. 2d 365 (S.D.N.Y. 2009) (No. 09 Civ. 4515). However, the court
denied the motions. Ass'n for Molecular Pathology, 669 F. Supp. 2d at 370.
While the USPTO is correct that Myriad's refusal to license its patent broadly contributes to
Plaintiffs' alleged injuries, the patents were issued by the USPTO, in accordance with its poli-
cies and practices. It is those policies and practices that the Plaintiffs allege are unconstitu-
tional. The injury alleged is therefore "fairly traceable" to the USPTO.
... Granting Plaintiffs' request for relief would serve to render the claims-at-issue defini-
tionally invalid. As a result, the Plaintiffs would be allowed to engage in conduct currently
prohibited by Myriad's patents, and the alleged injuries would be redressed.
Id. at 385 (quotations omitted).
168. W. Edward Ramage, The Aftermath of 'Myriad Genetics,' LAW,COM, Jun. 1, 2010,
http://www.law.com/jsp/article.jsp?id= I202458973843&TheAftermath_oLMyriadGenetic.
169. Id.
170. Id.
171. Id.
172. Ass'n for Molecular Pathology, 669 F. Supp. 2d at 370. The challenges to the BRCA
patents "raise questions of difficult legal dimensions concerning constitutional protections," as
well as "the need to adopt policies that promote scientific innovation in biomedical research."
Id. The outcome of the case against the USPTO and Myriad, and the resolution of the novel
legal issues "will have far-reaching implications, not only for gene-based health care .... but
also for the future course of biomedical research." Id.
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the patenting of genes, in general. 113 However, in order to maximize the
benefits to the public, it is necessary that genetic testing is widely available
with the greatest possible quality. The case against the USPTO and Myriad
is rather a way to demonstrate the actual harms of broad patenting and licens-
ing schemes in such an unknown yet valuable realm of information and
sciences.
A recent case, Prometheus Laboratories, Inc. v. Mayo Collaborative
Services,174 held that a correlation between metabolite levels and toxic results
from metabolic activity in the human body were natural, unpatentable, phe-
nomena, that would have existed without human intervention. 175  Certain
natural metabolites were not patentable on their own because the correlation
was a result from a natural body process. 176 However, with Judge Sweet's
new opinion, there might be hope that an appeals court may still hold that the
mutations on the BRCA genes-while believed to be environmentally caused
in an isolated, purified gene-are naturally correlated with a higher risk of
breast cancer, and are therefore not patentable. It will likely take years of
litigation to see whether Myriad's patents will meet whatever standard the
Supreme Court devises in the future.177
Perhaps the answer to gene patents might be to develop a patenting
scheme where there would still be incentive for intellectual efforts by ensur-
ing financial merit; but, instead of granting exclusive rights and licenses, the
patent would allow certain health-care providers access without infringe-
ment, or perhaps setting limits on licensing fees so that there would be de-
creased insurance barriers to patient access to quality healthcare. 178 Further-
173. Because only some of Myriad's claims were invalidated, while some remained un-
challenged. Ramage, supra note 168.
174. No. 04cvl200JAH(RBB), 2008 WL 878910, at *1 (S.D. Cal. Mar. 28, 2008), rev'd,
581 F.3d 1336 (Fed. Cir. 2009).
175. Id. at *6-9.
176. Id. at *7.
177. Susan Decker & Thom Weidlich, Myriad Loses Ruling over Breast Cancer-Gene
Patents (Update3), BLOOMBERG BUSINESSWEEK, Mar. 29, 2010, http://www.businessweek.
com/news/2010-03-29/myriad-loses-ruling-over-breast-cancer-gene-patents-update l-.html.
178. After completion of author's own research, conclusions, and recommendations-as
stated in Part IV of this article-the Secretary's Advisory Committee on Genetics, Health and
Society (SACGHS) for the Department of Health and Human Services (HHS) issued a revised
draft report, entitled Gene Patents and Licensing Practices and Their Impact on Patient
Access to Genetic Tests, which includes six recommendations that stress equal and uninhibited
access to the benefits of genetic testing and research for Plaintiffs like those affected by the
broad BRCA patents. See SECRETARY'S ADVISORY COMM. ON GENETICS, HEALTH, AND
SOCIETY, REVISED DRAFr REPORT ON GENE PATENTS AND LICENSING PRACTICES AND THEIR
IMPACT ON PATIENT ACCESS TO GENETIC TESTS 2 (Feb. 5, 2010), available at http://
oba.od.nih.gov/oba/SACGHS/SACGHS%20Patents%20Report%20Approved%202-5-20010.
[Vol. 34
26
Nova Law Review, Vol. 34, Iss. 3 [2010], Art. 16
http://nsuworks.nova.edu/nlr/vol34/iss3/16
CONSTITUTIONALITY OF PATENTING BRCA GENES
more, if the same genetic test could be performed with better quality and
knowledge by someone who has greater skills than that of Myriad, the gov-
ernment should not allow the public to suffer as a result. The personal right
of those wishing to exercise their constitutional rights to access and share
information and make informed decisions over their body should not be ab-
ridged simply because a court has read a patent too broadly.
pdf. The most controversial recommendation is "Recommendation 1: Support the Creation of
Exemptions from Infringement Liability," which suggests carving out statutory "exemption[s]
from liability for infringement of patent claims on genes for anyone making, using, ordering,
offering for sale, or selling a test developed under the patent for patient care purposes," and
"for those who use patent-protected genes in the pursuit of research." Id. at 90. The other
recommendations are as follows: "Recommendation 2: Promote Adherence to Norms De-
signed to Ensure Access"; "Recommendation 3: Enhance Transparency in Licensing"; "Rec-
ommendation 4: Establish an Advisory Body on the Health Impact of Gene Patenting and
Licensing Practices"; "Recommendation 5: Provide Needed Expertise to USPTO"; and "Rec-
ommendation 6: Ensure Equal Access to Clinically Useful Genetic Tests." Id. at 91-93.
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